MENA Active Pharmaceutical Ingredient Market Report: Trends, Forecast and Competitive Analysis
The future of the Middle Eastern and North African active pharmaceutical ingredient market looks promising with opportunities in the cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory therapeutic areas. The Middle Eastern and North African active pharmaceutical ingredient market is expected to reach $5.2 billion and grow with a CAGR of 6%- 8% from 2019 to 2025. The major drivers for this market are rise in growth of pharmaceutical production and research and development of new drugs.
Emerging trends, which have direct impact on the dynamics of the industry, include increase in adoption of advance technologies in API manufacturing, increasing demand for high potency APIs, and increasing adoption of binder for development of peroxide sensitive APIs.
A total of 95 figures/charts and 71 tables are provided in this 158-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the Middle Eastern and North African active pharmaceutical ingredient market report, please download the report brochure.
Middle Eastern and North African active pharmaceutical ingredient
Middle Eastern and North African active pharmaceutical ingredient
The study includes trends and forecast for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type, manufacturer type, therapeutic area, product form, molecule type, and drug type as follows:
By Synthesis Type [Value ($ Million) for 2014 – 2025]:
Synthetic ChemicalBiotech and BiologicsPlant ExtractsFermentationOthers
By Manufacturer Type [Value ($ Million) for 2014 – 2025]:
Captive APIsMerchant APIs
By Therapeutic Area [Value ($ Million) for 2014 – 2025]:
CardiologyOncologyNeurologyOphthalmologyOrthopedicsPulmonologyAlimentAnti-InflammatoryOthers
By Product Form [Value ($ Million) for 2014 – 2025]:
Liquid API Powder API
By Molecule Type [Value ($ Million) for 2014 – 2025]:
Large MoleculeSmall Molecule
By Drug Type [Value ($ Million) for 2014 – 2025]:
BrandedGenericOver-the-Counter
Some of the active pharmaceutical ingredient companies profiled in this report include Pfizer, Teva Pharmaceutical, GSK, Sun Pharmaceutical, Novartis, Aurobindo, Merck& Co., BASF, Julphar, and AbbVie.
Lucintel forecasts that synthetic chemical will remain the largest segment over the forecast period due to continuous research and development activities and growing demand of synthetic chemical APIs in therapeutic areas.
Within this market, cardiology will remain the largest therapeutic area segment over the forecast period due to increasing cardiovascular diseases and increase in geriatric population.
Features of the Middle Eastern and North African active pharmaceutical ingredient Market
Market Size Estimates: Middle Eastern and North African active pharmaceutical ingredient market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Middle Eastern and North African active pharmaceutical ingredient market size by various segments, such as synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type in terms of value.Country Analysis: Middle Eastern and North African active pharmaceutical ingredient market breakdown by the Saudi Arabia.Growth Opportunities: Analysis of growth opportunities in different synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type for the Middle Eastern and North African active pharmaceutical ingredient market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Middle Eastern and North African active pharmaceutical ingredient market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following 11 key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type (synthetic chemical, biotech and biologics, plant extracts, fermentation, and others), manufacturer type (captive apis and merchant apis), therapeutic area (cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory, and others ), product form (liquid api and powder api), molecule type (large molecule and small molecule), and drug type (branded, generic, and over-the-counter)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which country will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the Middle Eastern and North African active pharmaceutical ingredient market?
Q.5 What are the business risks and threats to the Middle Eastern and North African active pharmaceutical ingredient market?
Q.6 What are emerging trends in this active pharmaceutical ingredient market and the reasons behind them?
Q.7 What are some changing demands of customers in this active pharmaceutical ingredient market?
Q.8 What are the new developments in this active pharmaceutical ingredient market? Which companies are leading these developments?
Q.9 Who are the major players in this active pharmaceutical ingredient market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this active pharmaceutical ingredient market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the Middle Eastern and North African active pharmaceutical ingredient market?The future of the Middle Eastern and North African active pharmaceutical ingredient market looks promising with opportunities in the cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory therapeutic areas. The Middle Eastern and North African active pharmaceutical ingredient market is expected to reach $5.2 billion and grow with a CAGR of 6%- 8% from 2019 to 2025. The major drivers for this market are rise in growth of pharmaceutical production and research and development of new drugs.
Emerging trends, which have direct impact on the dynamics of the industry, include increase in adoption of advance technologies in API manufacturing, increasing demand for high potency APIs, and increasing adoption of binder for development of peroxide sensitive APIs.
A total of 95 figures/charts and 71 tables are provided in this 158-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the Middle Eastern and North African active pharmaceutical ingredient market report, please download the report brochure.
Middle Eastern and North African active pharmaceutical ingredient
Middle Eastern and North African active pharmaceutical ingredient
The study includes trends and forecast for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type, manufacturer type, therapeutic area, product form, molecule type, and drug type as follows:
By Synthesis Type [Value ($ Million) for 2014 – 2025]:
Synthetic ChemicalBiotech and BiologicsPlant ExtractsFermentationOthers
By Manufacturer Type [Value ($ Million) for 2014 – 2025]:
Captive APIsMerchant APIs
By Therapeutic Area [Value ($ Million) for 2014 – 2025]:
CardiologyOncologyNeurologyOphthalmologyOrthopedicsPulmonologyAlimentAnti-InflammatoryOthers
By Product Form [Value ($ Million) for 2014 – 2025]:
Liquid API Powder API
By Molecule Type [Value ($ Million) for 2014 – 2025]:
Large MoleculeSmall Molecule
By Drug Type [Value ($ Million) for 2014 – 2025]:
BrandedGenericOver-the-Counter
Some of the active pharmaceutical ingredient companies profiled in this report include Pfizer, Teva Pharmaceutical, GSK, Sun Pharmaceutical, Novartis, Aurobindo, Merck& Co., BASF, Julphar, and AbbVie.
Lucintel forecasts that synthetic chemical will remain the largest segment over the forecast period due to continuous research and development activities and growing demand of synthetic chemical APIs in therapeutic areas.
Within this market, cardiology will remain the largest therapeutic area segment over the forecast period due to increasing cardiovascular diseases and increase in geriatric population.
Features of the Middle Eastern and North African active pharmaceutical ingredient Market
Market Size Estimates: Middle Eastern and North African active pharmaceutical ingredient market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Middle Eastern and North African active pharmaceutical ingredient market size by various segments, such as synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type in terms of value.Country Analysis: Middle Eastern and North African active pharmaceutical ingredient market breakdown by the Saudi Arabia.Growth Opportunities: Analysis of growth opportunities in different synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type for the Middle Eastern and North African active pharmaceutical ingredient market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Middle Eastern and North African active pharmaceutical ingredient market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following 11 key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type (synthetic chemical, biotech and biologics, plant extracts, fermentation, and others), manufacturer type (captive apis and merchant apis), therapeutic area (cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory, and others ), product form (liquid api and powder api), molecule type (large molecule and small molecule), and drug type (branded, generic, and over-the-counter)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which country will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the Middle Eastern and North African active pharmaceutical ingredient market?
Q.5 What are the business risks and threats to the Middle Eastern and North African active pharmaceutical ingredient market?
Q.6 What are emerging trends in this active pharmaceutical ingredient market and the reasons behind them?
Q.7 What are some changing demands of customers in this active pharmaceutical ingredient market?
Q.8 What are the new developments in this active pharmaceutical ingredient market? Which companies are leading these developments?
Q.9 Who are the major players in this active pharmaceutical ingredient market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this active pharmaceutical ingredient market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the Middle Eastern and North African active pharmaceutical ingredient market?
Emerging trends, which have direct impact on the dynamics of the industry, include increase in adoption of advance technologies in API manufacturing, increasing demand for high potency APIs, and increasing adoption of binder for development of peroxide sensitive APIs.
A total of 95 figures/charts and 71 tables are provided in this 158-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the Middle Eastern and North African active pharmaceutical ingredient market report, please download the report brochure.
Middle Eastern and North African active pharmaceutical ingredient
Middle Eastern and North African active pharmaceutical ingredient
The study includes trends and forecast for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type, manufacturer type, therapeutic area, product form, molecule type, and drug type as follows:
By Synthesis Type [Value ($ Million) for 2014 – 2025]:
Synthetic ChemicalBiotech and BiologicsPlant ExtractsFermentationOthers
By Manufacturer Type [Value ($ Million) for 2014 – 2025]:
Captive APIsMerchant APIs
By Therapeutic Area [Value ($ Million) for 2014 – 2025]:
CardiologyOncologyNeurologyOphthalmologyOrthopedicsPulmonologyAlimentAnti-InflammatoryOthers
By Product Form [Value ($ Million) for 2014 – 2025]:
Liquid API Powder API
By Molecule Type [Value ($ Million) for 2014 – 2025]:
Large MoleculeSmall Molecule
By Drug Type [Value ($ Million) for 2014 – 2025]:
BrandedGenericOver-the-Counter
Some of the active pharmaceutical ingredient companies profiled in this report include Pfizer, Teva Pharmaceutical, GSK, Sun Pharmaceutical, Novartis, Aurobindo, Merck& Co., BASF, Julphar, and AbbVie.
Lucintel forecasts that synthetic chemical will remain the largest segment over the forecast period due to continuous research and development activities and growing demand of synthetic chemical APIs in therapeutic areas.
Within this market, cardiology will remain the largest therapeutic area segment over the forecast period due to increasing cardiovascular diseases and increase in geriatric population.
Features of the Middle Eastern and North African active pharmaceutical ingredient Market
Market Size Estimates: Middle Eastern and North African active pharmaceutical ingredient market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Middle Eastern and North African active pharmaceutical ingredient market size by various segments, such as synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type in terms of value.Country Analysis: Middle Eastern and North African active pharmaceutical ingredient market breakdown by the Saudi Arabia.Growth Opportunities: Analysis of growth opportunities in different synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type for the Middle Eastern and North African active pharmaceutical ingredient market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Middle Eastern and North African active pharmaceutical ingredient market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following 11 key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type (synthetic chemical, biotech and biologics, plant extracts, fermentation, and others), manufacturer type (captive apis and merchant apis), therapeutic area (cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory, and others ), product form (liquid api and powder api), molecule type (large molecule and small molecule), and drug type (branded, generic, and over-the-counter)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which country will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the Middle Eastern and North African active pharmaceutical ingredient market?
Q.5 What are the business risks and threats to the Middle Eastern and North African active pharmaceutical ingredient market?
Q.6 What are emerging trends in this active pharmaceutical ingredient market and the reasons behind them?
Q.7 What are some changing demands of customers in this active pharmaceutical ingredient market?
Q.8 What are the new developments in this active pharmaceutical ingredient market? Which companies are leading these developments?
Q.9 Who are the major players in this active pharmaceutical ingredient market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this active pharmaceutical ingredient market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the Middle Eastern and North African active pharmaceutical ingredient market?The future of the Middle Eastern and North African active pharmaceutical ingredient market looks promising with opportunities in the cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory therapeutic areas. The Middle Eastern and North African active pharmaceutical ingredient market is expected to reach $5.2 billion and grow with a CAGR of 6%- 8% from 2019 to 2025. The major drivers for this market are rise in growth of pharmaceutical production and research and development of new drugs.
Emerging trends, which have direct impact on the dynamics of the industry, include increase in adoption of advance technologies in API manufacturing, increasing demand for high potency APIs, and increasing adoption of binder for development of peroxide sensitive APIs.
A total of 95 figures/charts and 71 tables are provided in this 158-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the Middle Eastern and North African active pharmaceutical ingredient market report, please download the report brochure.
Middle Eastern and North African active pharmaceutical ingredient
Middle Eastern and North African active pharmaceutical ingredient
The study includes trends and forecast for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type, manufacturer type, therapeutic area, product form, molecule type, and drug type as follows:
By Synthesis Type [Value ($ Million) for 2014 – 2025]:
Synthetic ChemicalBiotech and BiologicsPlant ExtractsFermentationOthers
By Manufacturer Type [Value ($ Million) for 2014 – 2025]:
Captive APIsMerchant APIs
By Therapeutic Area [Value ($ Million) for 2014 – 2025]:
CardiologyOncologyNeurologyOphthalmologyOrthopedicsPulmonologyAlimentAnti-InflammatoryOthers
By Product Form [Value ($ Million) for 2014 – 2025]:
Liquid API Powder API
By Molecule Type [Value ($ Million) for 2014 – 2025]:
Large MoleculeSmall Molecule
By Drug Type [Value ($ Million) for 2014 – 2025]:
BrandedGenericOver-the-Counter
Some of the active pharmaceutical ingredient companies profiled in this report include Pfizer, Teva Pharmaceutical, GSK, Sun Pharmaceutical, Novartis, Aurobindo, Merck& Co., BASF, Julphar, and AbbVie.
Lucintel forecasts that synthetic chemical will remain the largest segment over the forecast period due to continuous research and development activities and growing demand of synthetic chemical APIs in therapeutic areas.
Within this market, cardiology will remain the largest therapeutic area segment over the forecast period due to increasing cardiovascular diseases and increase in geriatric population.
Features of the Middle Eastern and North African active pharmaceutical ingredient Market
Market Size Estimates: Middle Eastern and North African active pharmaceutical ingredient market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Middle Eastern and North African active pharmaceutical ingredient market size by various segments, such as synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type in terms of value.Country Analysis: Middle Eastern and North African active pharmaceutical ingredient market breakdown by the Saudi Arabia.Growth Opportunities: Analysis of growth opportunities in different synthesis type, manufacturer type, therapeutic area, product form, molecular type, and drug type for the Middle Eastern and North African active pharmaceutical ingredient market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Middle Eastern and North African active pharmaceutical ingredient market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following 11 key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the Middle Eastern and North African active pharmaceutical ingredient market by synthesis type (synthetic chemical, biotech and biologics, plant extracts, fermentation, and others), manufacturer type (captive apis and merchant apis), therapeutic area (cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory, and others ), product form (liquid api and powder api), molecule type (large molecule and small molecule), and drug type (branded, generic, and over-the-counter)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which country will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the Middle Eastern and North African active pharmaceutical ingredient market?
Q.5 What are the business risks and threats to the Middle Eastern and North African active pharmaceutical ingredient market?
Q.6 What are emerging trends in this active pharmaceutical ingredient market and the reasons behind them?
Q.7 What are some changing demands of customers in this active pharmaceutical ingredient market?
Q.8 What are the new developments in this active pharmaceutical ingredient market? Which companies are leading these developments?
Q.9 Who are the major players in this active pharmaceutical ingredient market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this active pharmaceutical ingredient market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the Middle Eastern and North African active pharmaceutical ingredient market?
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Industry Drivers and Challenges
2.3: Supply Chain
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 TO 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Active Pharmaceutical Ingredient Market Trends and Forecast
3.3: MENA Active Pharmaceutical Ingredient Market Trends and Forecast
3.4: MENA Active Pharmaceutical Ingredient Market by Synthesis Type
3.4.1: Synthetic Chemical
3.4.2: Biotech and Biologics
3.4.3: Plant Extracts
3.4.4: Fermentation
3.4.5: Others
3.5: MENA Active Pharmaceutical Ingredient Market by Manufacturer Type
3.5.1: Captive APIs
3.5.2: Merchant APIs
3.6: MENA Active Pharmaceutical Ingredient Market by Therapeutic Area
3.6.1: Cardiology
3.6.2: Oncology
3.6.3: Neurology
3.6.4: Orthopedics
3.6.5: Ophthalmology
3.6.6: Pulmonology
3.6.7: Aliment
3.6.8: Anti-Inflammatory
3.6.9: Others
3.7: MENA Active Pharmaceutical Ingredient Market by Product Form
3.7.1: Liquid APIs
3.7.2: Powder APIs
3.8: MENA Active Pharmaceutical Ingredient Market by Molecule
3.8.1: Large Molecules
3.8.2: Small Molecules
3.9: MENA Active Pharmaceutical Ingredient Market by Drug Type
3.9.1: Branded
3.9.2: Generic
3.9.3: Over-the–Counter (OTC)
3.10: Saudi Arabian Active Pharmaceutical Ingredient Market
3.10.1: Market by Therapeutic Area: Cardiology, Oncology, Neurology, Orthopedics, Ophthalmology, Aliment, Anti-Inflammatory, and Others
4. COMPETITOR ANALYSIS
4.1: Product Portfolio Analysis
4.2: Market Share Analysis
4.3: Operational Integration
4.4: Geographical Reach
4.5: Porter’s Five Forces Analysis
5. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
5.1: Growth Opportunity Analysis
5.1.1: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Synthesis Type
5.1.2: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Manufacturer Type
5.1.3: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Therapeutic Area
5.1.4: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Product Form
5.1.5: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Molecule
5.1.6: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Drug Type
5.2: Emerging Trends in the MENA Active Pharmaceutical Ingredient Market
5.3: Strategic Analysis
5.3.1: New Technological Development
5.3.2: Mergers, Acquisitions, and Joint Ventures in the MENA Active Pharmaceutical Ingredient Market
5.3.3: Capacity Expansion of the MENA Active Pharmaceutical Ingredient Market
5.3.4: Certification and Licensing
6. COMPANY PROFILES OF LEADING PLAYERS
6.1: Pfizer Inc.
6.2: Teva Pharmaceutical Industries Ltd.
6.3: GlaxoSmithKline (GSK)
6.4: Sun Pharmaceutical Industries Ltd.
6.5: Novartis International AG
6.6: Aurobindo Pharma Ltd.
6.7: Merck & Co.
6.8: BASF SE
6.9: Julphar Pharmaceutical Company
6.10: AbbVie Inc.
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Industry Drivers and Challenges
2.3: Supply Chain
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 TO 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Active Pharmaceutical Ingredient Market Trends and Forecast
3.3: MENA Active Pharmaceutical Ingredient Market Trends and Forecast
3.4: MENA Active Pharmaceutical Ingredient Market by Synthesis Type
3.4.1: Synthetic Chemical
3.4.2: Biotech and Biologics
3.4.3: Plant Extracts
3.4.4: Fermentation
3.4.5: Others
3.5: MENA Active Pharmaceutical Ingredient Market by Manufacturer Type
3.5.1: Captive APIs
3.5.2: Merchant APIs
3.6: MENA Active Pharmaceutical Ingredient Market by Therapeutic Area
3.6.1: Cardiology
3.6.2: Oncology
3.6.3: Neurology
3.6.4: Orthopedics
3.6.5: Ophthalmology
3.6.6: Pulmonology
3.6.7: Aliment
3.6.8: Anti-Inflammatory
3.6.9: Others
3.7: MENA Active Pharmaceutical Ingredient Market by Product Form
3.7.1: Liquid APIs
3.7.2: Powder APIs
3.8: MENA Active Pharmaceutical Ingredient Market by Molecule
3.8.1: Large Molecules
3.8.2: Small Molecules
3.9: MENA Active Pharmaceutical Ingredient Market by Drug Type
3.9.1: Branded
3.9.2: Generic
3.9.3: Over-the–Counter (OTC)
3.10: Saudi Arabian Active Pharmaceutical Ingredient Market
3.10.1: Market by Therapeutic Area: Cardiology, Oncology, Neurology, Orthopedics, Ophthalmology, Aliment, Anti-Inflammatory, and Others
4. COMPETITOR ANALYSIS
4.1: Product Portfolio Analysis
4.2: Market Share Analysis
4.3: Operational Integration
4.4: Geographical Reach
4.5: Porter’s Five Forces Analysis
5. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
5.1: Growth Opportunity Analysis
5.1.1: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Synthesis Type
5.1.2: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Manufacturer Type
5.1.3: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Therapeutic Area
5.1.4: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Product Form
5.1.5: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Molecule
5.1.6: Growth Opportunities for the Middle Eastern and North African Active Pharmaceutical Ingredient Market by Drug Type
5.2: Emerging Trends in the MENA Active Pharmaceutical Ingredient Market
5.3: Strategic Analysis
5.3.1: New Technological Development
5.3.2: Mergers, Acquisitions, and Joint Ventures in the MENA Active Pharmaceutical Ingredient Market
5.3.3: Capacity Expansion of the MENA Active Pharmaceutical Ingredient Market
5.3.4: Certification and Licensing
6. COMPANY PROFILES OF LEADING PLAYERS
6.1: Pfizer Inc.
6.2: Teva Pharmaceutical Industries Ltd.
6.3: GlaxoSmithKline (GSK)
6.4: Sun Pharmaceutical Industries Ltd.
6.5: Novartis International AG
6.6: Aurobindo Pharma Ltd.
6.7: Merck & Co.
6.8: BASF SE
6.9: Julphar Pharmaceutical Company
6.10: AbbVie Inc.
LIST OF FIGURES
Chapter 2. Market Background and Classifications
Figure 2.1: Active Pharmaceutical Ingredient
Figure 2.2: Classification of the Active Pharmaceutical Ingredient Market
Figure 2.3: Major Drivers and Challenges for the MENA Active Pharmaceutical Ingredient Market
Figure 2.4: Supply Chain of the MENA Active Pharmaceutical Ingredient Market
Chapter 3. Market Trends and Forecast Analysis from 2014 to 2025
Figure 3.1: Trends and Forecast for the MENA GDP Growth Rate
Figure 3.2: Trends and Forecast for the MENA Population Growth Rate
Figure 3.3: Trends and Forecast for the MENA Inflation Rate
Figure 3.4: Trends and Forecast for the MENA Unemployment Rate
Figure 3.5: Trends and Forecast for the MENA Per Capita Income
Figure 3.6: Trends and Forecast for the Global Active Pharmaceutical Ingredient Market (2014-2025)
Figure 3.7: Trends and Forecast for the MENA Active Pharmaceutical Ingredient Market (2014-2025)
Figure 3.8: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Synthesis Type (2014-2019)
Figure 3.9: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Synthesis Type (2020-2025)
Figure 3.10: Trends of Synthetic Chemical in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.11: Forecast for Synthetic Chemical in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.12: Trends of Biotech and Biologics in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.13: Forecast for Biotech and Biologics in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.14: Trends of Plant Extracts in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.15: Forecast for Plant Extracts in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.16: Trends of Fermentation in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.17: Forecast for Fermentation in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.18: Trends of Other Synthesis Type in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.19: Forecast for Other Synthesis Type in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.20: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Manufacturer Type (2014- 2019)
Figure 3.21: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Manufacturer Type (2020-2025)
Figure 3.22: Trends of Captive APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.23: Forecast for Captive APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.24: Trends of Merchant APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.25: Forecast for Merchant APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.26: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Therapeutic Area (2014-2019)
Figure 3.27: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Therapeutic Area (2020-2025)
Figure 3.28: Trends of Cardiology in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.29: Forecast for Cardiology in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.30: Trends of Oncology in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.31: Forecast for Oncology in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.32: Trends of Neurology in the MENA Active Pharmaceutical Ingredient ($M) (2014-2019)
Figure 3.33: Forecast for Neurology in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.34: Trends of Orthopedics in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.35: Forecast for Orthopedics in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.36: Trends of Ophthalmology in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.37: Forecast for Ophthalmology in the MENA Active Pharmaceutical Ingredient Market ($M) by Region (2020-2025)
Figure 3.38: Trends of Pulmonology in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.39: Forecast for Pulmonology in the MENA Active Pharmaceutical Ingredient Market ($M) by Region (2020-2025)
Figure 3.40: Trends of Aliment in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.41: Forecast for Aliment in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.42: Trends of Anti-Inflammatory in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.43: Forecast for Anti-Inflammatory in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.44: Trends of Other Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.45: Forecast for Other Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.46: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Product Form (2014-2019)
Figure 3.47: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Product Form (2020-2025)
Figure 3.48: Trends of Liquid APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.49: Forecast for Liquid APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.50: Trends of Powder APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.51: Forecast for Powder APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.52: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Molecule (2014-2019)
Figure 3.53: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Molecule (2020-2025)
Figure 3.54: Trends of Large Molecules in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.55: Forecast for Large Molecules in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.56: Trends of Small Molecules in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.57: Forecast for Small Molecules in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.58: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Drug Type (2014- 2019)
Figure 3.59: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Drug Type (2020-2025)
Figure 3.60: Trends of Branded in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.61: Forecast for Branded in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.62: Trends of Generic in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.63: Forecast for Generic in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.64: Trends of Over-the-Counter in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.65: Forecast for Over-the-Counter in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.66: Trends and Forecast for the Saudi Arabian Active Pharmaceutical Ingredient Market (2014-2025)
Figure 3.67: Trends of the Saudi Arabian Active Pharmaceutical Ingredient Market ($M) by Therapeutic Area (2014-2019)
Figure 3.68: Forecast for the Saudi Arabian Active Pharmaceutical Ingredient Market ($M) by Therapeutic Area (2020-2025)
Table 3.69: Market Size and CAGR of Various Therapeutic Areas of the Saudi Arabian Active Pharmaceutical Ingredient Market by Value (2014-2019)
Chapter 4. Competitor Analysis
Figure 4.1: Market Share Analysis of the MENA API Market in 2019
Figure 4.2: Market Share Analysis of Top Five Players in the MENA API Market in 2019
Figure 4.3: Major Locations of Competitors in the MENA Active Pharmaceutical Ingredient Market
Figure 4.4: Porter’s Five Forces Analysis of the MENA Active Pharmaceutical Ingredient Market
Chapter 5. Growth Opportunities and Strategic Analysis
Figure 5.1: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Synthesis Type (2020-2025)
Figure 5.2: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Manufacturer Type (2020-2025)
Figure 5.3: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Therapeutic Area (2020-2025)
Figure 5.4: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Product Form (2020-2025)
Figure 5.5: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Molecule (2020-2025)
Figure 5.6: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Drug Type (2020-2025)
Figure 5.7: Emerging Trends in the MENA Active Pharmaceutical Ingredient Market
Figure 5.8: Major Capacity Expansions in the MENA Active Pharmaceutical Ingredient Market (2014-2019)
Chapter 6. Company Profiles of Leading Players
Figure 6.1: Headquarter Location of Pfizer Inc.
Figure 6.2: Headquarter Location of Teva Pharmaceutical Industries Ltd.
Figure 6.3: Headquarter Location of GlaxoSmithKline (GSK)
Figure 6.4: Manufacturing Location of Sun Pharmaceutical Industries Ltd.
Figure 6.5: Headquarter Location of Novartis International AG.
Figure 6.6: Headquarter Location of Aurobindo Pharma Ltd.
Figure 6.7: Headquarter Location of Merck & Co.
Figure 6.8: Headquarter Location of BASF SE
Figure 6.9: Headquarter Locations of Julphar Pharmaceutical Company
Figure 6.10: Headquarter Location of AbbVie Inc.
Chapter 2. Market Background and Classifications
Figure 2.1: Active Pharmaceutical Ingredient
Figure 2.2: Classification of the Active Pharmaceutical Ingredient Market
Figure 2.3: Major Drivers and Challenges for the MENA Active Pharmaceutical Ingredient Market
Figure 2.4: Supply Chain of the MENA Active Pharmaceutical Ingredient Market
Chapter 3. Market Trends and Forecast Analysis from 2014 to 2025
Figure 3.1: Trends and Forecast for the MENA GDP Growth Rate
Figure 3.2: Trends and Forecast for the MENA Population Growth Rate
Figure 3.3: Trends and Forecast for the MENA Inflation Rate
Figure 3.4: Trends and Forecast for the MENA Unemployment Rate
Figure 3.5: Trends and Forecast for the MENA Per Capita Income
Figure 3.6: Trends and Forecast for the Global Active Pharmaceutical Ingredient Market (2014-2025)
Figure 3.7: Trends and Forecast for the MENA Active Pharmaceutical Ingredient Market (2014-2025)
Figure 3.8: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Synthesis Type (2014-2019)
Figure 3.9: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Synthesis Type (2020-2025)
Figure 3.10: Trends of Synthetic Chemical in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.11: Forecast for Synthetic Chemical in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.12: Trends of Biotech and Biologics in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.13: Forecast for Biotech and Biologics in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.14: Trends of Plant Extracts in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.15: Forecast for Plant Extracts in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.16: Trends of Fermentation in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.17: Forecast for Fermentation in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.18: Trends of Other Synthesis Type in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.19: Forecast for Other Synthesis Type in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.20: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Manufacturer Type (2014- 2019)
Figure 3.21: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Manufacturer Type (2020-2025)
Figure 3.22: Trends of Captive APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.23: Forecast for Captive APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.24: Trends of Merchant APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.25: Forecast for Merchant APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.26: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Therapeutic Area (2014-2019)
Figure 3.27: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Therapeutic Area (2020-2025)
Figure 3.28: Trends of Cardiology in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.29: Forecast for Cardiology in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.30: Trends of Oncology in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.31: Forecast for Oncology in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.32: Trends of Neurology in the MENA Active Pharmaceutical Ingredient ($M) (2014-2019)
Figure 3.33: Forecast for Neurology in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.34: Trends of Orthopedics in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.35: Forecast for Orthopedics in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.36: Trends of Ophthalmology in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.37: Forecast for Ophthalmology in the MENA Active Pharmaceutical Ingredient Market ($M) by Region (2020-2025)
Figure 3.38: Trends of Pulmonology in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.39: Forecast for Pulmonology in the MENA Active Pharmaceutical Ingredient Market ($M) by Region (2020-2025)
Figure 3.40: Trends of Aliment in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.41: Forecast for Aliment in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.42: Trends of Anti-Inflammatory in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.43: Forecast for Anti-Inflammatory in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.44: Trends of Other Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.45: Forecast for Other Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.46: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Product Form (2014-2019)
Figure 3.47: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Product Form (2020-2025)
Figure 3.48: Trends of Liquid APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.49: Forecast for Liquid APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.50: Trends of Powder APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.51: Forecast for Powder APIs in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.52: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Molecule (2014-2019)
Figure 3.53: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Molecule (2020-2025)
Figure 3.54: Trends of Large Molecules in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.55: Forecast for Large Molecules in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.56: Trends of Small Molecules in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.57: Forecast for Small Molecules in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.58: Trends of the MENA Active Pharmaceutical Ingredient Market ($M) by Drug Type (2014- 2019)
Figure 3.59: Forecast for the MENA Active Pharmaceutical Ingredient Market ($M) by Drug Type (2020-2025)
Figure 3.60: Trends of Branded in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.61: Forecast for Branded in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.62: Trends of Generic in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.63: Forecast for Generic in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.64: Trends of Over-the-Counter in the MENA Active Pharmaceutical Ingredient Market ($M) (2014-2019)
Figure 3.65: Forecast for Over-the-Counter in the MENA Active Pharmaceutical Ingredient Market ($M) (2020-2025)
Figure 3.66: Trends and Forecast for the Saudi Arabian Active Pharmaceutical Ingredient Market (2014-2025)
Figure 3.67: Trends of the Saudi Arabian Active Pharmaceutical Ingredient Market ($M) by Therapeutic Area (2014-2019)
Figure 3.68: Forecast for the Saudi Arabian Active Pharmaceutical Ingredient Market ($M) by Therapeutic Area (2020-2025)
Table 3.69: Market Size and CAGR of Various Therapeutic Areas of the Saudi Arabian Active Pharmaceutical Ingredient Market by Value (2014-2019)
Chapter 4. Competitor Analysis
Figure 4.1: Market Share Analysis of the MENA API Market in 2019
Figure 4.2: Market Share Analysis of Top Five Players in the MENA API Market in 2019
Figure 4.3: Major Locations of Competitors in the MENA Active Pharmaceutical Ingredient Market
Figure 4.4: Porter’s Five Forces Analysis of the MENA Active Pharmaceutical Ingredient Market
Chapter 5. Growth Opportunities and Strategic Analysis
Figure 5.1: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Synthesis Type (2020-2025)
Figure 5.2: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Manufacturer Type (2020-2025)
Figure 5.3: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Therapeutic Area (2020-2025)
Figure 5.4: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Product Form (2020-2025)
Figure 5.5: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Molecule (2020-2025)
Figure 5.6: Growth Opportunities for the MENA Active Pharmaceutical Ingredient Market by Drug Type (2020-2025)
Figure 5.7: Emerging Trends in the MENA Active Pharmaceutical Ingredient Market
Figure 5.8: Major Capacity Expansions in the MENA Active Pharmaceutical Ingredient Market (2014-2019)
Chapter 6. Company Profiles of Leading Players
Figure 6.1: Headquarter Location of Pfizer Inc.
Figure 6.2: Headquarter Location of Teva Pharmaceutical Industries Ltd.
Figure 6.3: Headquarter Location of GlaxoSmithKline (GSK)
Figure 6.4: Manufacturing Location of Sun Pharmaceutical Industries Ltd.
Figure 6.5: Headquarter Location of Novartis International AG.
Figure 6.6: Headquarter Location of Aurobindo Pharma Ltd.
Figure 6.7: Headquarter Location of Merck & Co.
Figure 6.8: Headquarter Location of BASF SE
Figure 6.9: Headquarter Locations of Julphar Pharmaceutical Company
Figure 6.10: Headquarter Location of AbbVie Inc.
LIST OF TABLES
Chapter 1. Executive Summary
Table 1.1: MENA Active Pharmaceutical Ingredient Market Parameters and Attributes
Chapter 3. Market Trends and Forecast Analysis from 2014 to 2025
Table 3.1: Market Trends of the Global Active Pharmaceutical Ingredient Market (2014-2019)
Table 3.2: Market Forecast for the Global Active Pharmaceutical Ingredient Market (2020-2025)
Table 3.3: Market Trends of the MENA Active Pharmaceutical Ingredient Market (2014-2019)
Table 3.4: Market Forecast for the MENA Active Pharmaceutical Ingredient Market (2020-2025)
Table 3.5: Market Size and CAGR of Various Synthesis Types in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.6: Market Size and CAGR of Various Synthesis Types of the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.7: Market Size and CAGR of Synthetic Chemical in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.8: Market Size and CAGR of Synthetic Chemical in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.9: Market Size and CAGR of Biotech and Biologics in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.10: Market Size and CAGR of Biotech and Biologics in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.11: Market Size and CAGR of Plant Extracts in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.12: Market Size and CAGR of Plant Extracts in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.13: Market Size and CAGR of Fermentation in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.14: Market Size and CAGR of Fermentation in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.15: Market Size and CAGR of Other Synthesis Type in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.16: Market Size and CAGR Other Synthesis Type in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.17: Market Size and CAGR of Various Manufacturer Types in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.18: Market Size and CAGR of Various Manufacturer Types in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.19: Market Size and CAGR of Captive APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.20: Market Size and CAGR of Captive APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.21: Market Size and CAGR of Merchant APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.22: Market Size and CAGR of Merchant APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.23: Market Size and CAGR of Various Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.24: Market Size and CAGR of Various Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.25: Market Size and CAGR of Cardiology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.26: Market Size and CAGR of Cardiology in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.27: Market Size and CAGR of Oncology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.28: Market Size and CAGR of Oncology in the MENA Active Pharmaceutical Ingredient Market (2020-2025)
Table 3.29: Market Size and CAGR of Neurology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.30: Market Size and CAGR of Neurology in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.31: Market Size and CAGR of Orthopedics in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.32: Market Size and CAGR of Orthopedics in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.33: Market Size and CAGR of Ophthalmology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.34: Market Size and CAGR of Ophthalmology in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.35: Market Size and CAGR of Pulmonology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.36: Market Size and CAGR of Pulmonology in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.37: Market Size and CAGR of Aliment in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.38: Market Size and CAGR of Aliment in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.39: Market Size and CAGR of Anti-Inflammatory in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.40: Market Size and CAGR of Anti-Inflammatory in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.41: Market Size and CAGR of Other Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.42: Market Size and CAGR of Other therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.43: Market Size and CAGR of Various Product Forms in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.44: Market Size and CAGR of Various Product Forms in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.45: Market Size and CAGR of Liquid APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.46: Market Size and CAGR of Liquid APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.47: Market Size and CAGR of Powder APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.48: Market Size and CAGR of Powder APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.49: Market Size and CAGR of Various Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.50: Market Size and CAGR of Various Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.51: Market Size and CAGR of Large Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.52: Market Size and CAGR of Large Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.53: Market Size and CAGR of Small Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.54: Market Size and CAGR of Small Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.55: Market Size and CAGR of Various Drug Types in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.56: Market Size and CAGR of Various Drug Types of the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.57: Market Size and CAGR of Branded in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.58: Market Size and CAGR of Branded in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.59: Market Size and CAGR of Generic in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.60: Market Size and CAGR of Generic in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.61: Market Size and CAGR of Over-the-Counter in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.62: Market Size and CAGR of Over-the-Counter in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.63: Market Trends of the Saudi Arabian Active Pharmaceutical Ingredient Market (2014-2019)
Table 3.64: Market Forecast for the Saudi Arabian Active Pharmaceutical Ingredient Market (2020-2025)
Table 3.65: Market Size and CAGR of Various Therapeutic Areas of the Saudi Arabian Active Pharmaceutical Ingredient Market by Value (2020-2025)
Chapter 4. Competitor Analysis
Table 4.1: Product Mapping of MENA Active Pharmaceutical Ingredient Suppliers Based on Markets Served
Table 4.2: Rankings of Public Suppliers Based on the MENA API Market Revenue
Table 4.3: Operational Integration of MENA API Suppliers
Chapter 5. Growth Opportunities and Strategic Analysis
Table 5.1: New Technological Developments by Major Active Pharmaceutical Ingredient Manufacturers (2014-2019) (Source: Lucintel)
Table 5.2: Certifications and Licenses Acquired by Major Competitors in the MENA Active Pharmaceutical Ingredient Market
Chapter 1. Executive Summary
Table 1.1: MENA Active Pharmaceutical Ingredient Market Parameters and Attributes
Chapter 3. Market Trends and Forecast Analysis from 2014 to 2025
Table 3.1: Market Trends of the Global Active Pharmaceutical Ingredient Market (2014-2019)
Table 3.2: Market Forecast for the Global Active Pharmaceutical Ingredient Market (2020-2025)
Table 3.3: Market Trends of the MENA Active Pharmaceutical Ingredient Market (2014-2019)
Table 3.4: Market Forecast for the MENA Active Pharmaceutical Ingredient Market (2020-2025)
Table 3.5: Market Size and CAGR of Various Synthesis Types in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.6: Market Size and CAGR of Various Synthesis Types of the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.7: Market Size and CAGR of Synthetic Chemical in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.8: Market Size and CAGR of Synthetic Chemical in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.9: Market Size and CAGR of Biotech and Biologics in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.10: Market Size and CAGR of Biotech and Biologics in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.11: Market Size and CAGR of Plant Extracts in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.12: Market Size and CAGR of Plant Extracts in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.13: Market Size and CAGR of Fermentation in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.14: Market Size and CAGR of Fermentation in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.15: Market Size and CAGR of Other Synthesis Type in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.16: Market Size and CAGR Other Synthesis Type in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.17: Market Size and CAGR of Various Manufacturer Types in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.18: Market Size and CAGR of Various Manufacturer Types in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.19: Market Size and CAGR of Captive APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.20: Market Size and CAGR of Captive APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.21: Market Size and CAGR of Merchant APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.22: Market Size and CAGR of Merchant APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.23: Market Size and CAGR of Various Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.24: Market Size and CAGR of Various Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.25: Market Size and CAGR of Cardiology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.26: Market Size and CAGR of Cardiology in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.27: Market Size and CAGR of Oncology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.28: Market Size and CAGR of Oncology in the MENA Active Pharmaceutical Ingredient Market (2020-2025)
Table 3.29: Market Size and CAGR of Neurology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.30: Market Size and CAGR of Neurology in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.31: Market Size and CAGR of Orthopedics in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.32: Market Size and CAGR of Orthopedics in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.33: Market Size and CAGR of Ophthalmology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.34: Market Size and CAGR of Ophthalmology in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.35: Market Size and CAGR of Pulmonology in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.36: Market Size and CAGR of Pulmonology in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.37: Market Size and CAGR of Aliment in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.38: Market Size and CAGR of Aliment in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.39: Market Size and CAGR of Anti-Inflammatory in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.40: Market Size and CAGR of Anti-Inflammatory in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.41: Market Size and CAGR of Other Therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.42: Market Size and CAGR of Other therapeutic Areas in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.43: Market Size and CAGR of Various Product Forms in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.44: Market Size and CAGR of Various Product Forms in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.45: Market Size and CAGR of Liquid APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.46: Market Size and CAGR of Liquid APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.47: Market Size and CAGR of Powder APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.48: Market Size and CAGR of Powder APIs in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.49: Market Size and CAGR of Various Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.50: Market Size and CAGR of Various Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.51: Market Size and CAGR of Large Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.52: Market Size and CAGR of Large Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.53: Market Size and CAGR of Small Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.54: Market Size and CAGR of Small Molecules in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.55: Market Size and CAGR of Various Drug Types in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.56: Market Size and CAGR of Various Drug Types of the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.57: Market Size and CAGR of Branded in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.58: Market Size and CAGR of Branded in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.59: Market Size and CAGR of Generic in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.60: Market Size and CAGR of Generic in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.61: Market Size and CAGR of Over-the-Counter in the MENA Active Pharmaceutical Ingredient Market by Value (2014-2019)
Table 3.62: Market Size and CAGR of Over-the-Counter in the MENA Active Pharmaceutical Ingredient Market by Value (2020-2025)
Table 3.63: Market Trends of the Saudi Arabian Active Pharmaceutical Ingredient Market (2014-2019)
Table 3.64: Market Forecast for the Saudi Arabian Active Pharmaceutical Ingredient Market (2020-2025)
Table 3.65: Market Size and CAGR of Various Therapeutic Areas of the Saudi Arabian Active Pharmaceutical Ingredient Market by Value (2020-2025)
Chapter 4. Competitor Analysis
Table 4.1: Product Mapping of MENA Active Pharmaceutical Ingredient Suppliers Based on Markets Served
Table 4.2: Rankings of Public Suppliers Based on the MENA API Market Revenue
Table 4.3: Operational Integration of MENA API Suppliers
Chapter 5. Growth Opportunities and Strategic Analysis
Table 5.1: New Technological Developments by Major Active Pharmaceutical Ingredient Manufacturers (2014-2019) (Source: Lucintel)
Table 5.2: Certifications and Licenses Acquired by Major Competitors in the MENA Active Pharmaceutical Ingredient Market
